CB
Cambrian BioPharma Inc
SEC filingBiotechnology · New York, NY
Amount raised$123.8Msold at filing
Total offering$129.8M$6M still open
Investors in the raise80count reported to the SEC
FiledJul 15, 2026first sale Jun 30, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
James PeyerExecutive Officer, Director
Mark NuttallExecutive Officer
Christian AngermeyerDirector
Brenton L. SaundersDirector
Martin L. GunhagaDirector
Juliette HanExecutive Officer, Director
Maryanna SaenkoDirector
Ruth Thieroff-EkerdtExecutive Officer
William DeVaulExecutive Officer
Lorin L. Van NulandDirector
Paul L. FarrDirector
Executive officers, directors and promoters as listed on the Form D.